Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2019

Mixed session - Melanoma

Response of nivolumab monotherapy in 124 Japanese patients with advanced melanoma: Interim analysis of prospective observational study (CREATIVE study)

Date

24 Nov 2019

Session

Mixed session - Melanoma

Topics

Tumour Site

Melanoma

Presenters

Naoya Yamazaki

Citation

Annals of Oncology (2019) 30 (suppl_9): ix115-ix117. 10.1093/annonc/mdz429

Authors

N. Yamazaki1, A. Takahashi2, K. Namikawa2, T. Takenouchi3, Y. Nakamura4, S. Kitano2, T. Fujita5, K. Kubota1, T. Yamanaka1, Y. Kawakami5

Author affiliations

  • 1 Department Of Biostatistics, Yokohama City University School of Medicine, 236-0004 - Yokohama/JP
  • 2 Dermatologic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3 Dermatology, Niigata Cancer Center Hospital, 951-8566 - Niigata/JP
  • 4 Skin Oncology/dermatolog, Saitama Medical University International Medical Center, 350-1298 - Saitama/JP
  • 5 Cellular Signaling Institute For Advanced Medical Research, Keio University School of Medicine, 1608582 - Tokyo/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.